Stocks · Healthcare · Biotechnology
Fulcrum Therapeutics, Inc. FULC
$3.69 +0.27% Close, Oct 2, 2026 · NASDAQ · Market cap $281.5M
Weak trendExpensive vs sector
Next earnings report: Oct 29, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 21.9% in a year.
- The stock is 75% below its highest close of the past year.
- Over the past year the stock returned -60.5%, behind the S&P 500 by 75.5 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 44%
- Accruals (lower is better)Bottom 46%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 22%
- Free-cash-flow yieldBottom 22%
- EBITDA / enterprise valueBottom 20%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 4%
- 6-month returnBottom 3%
- 1-year return vs S&P 500Bottom 6%
- Distance from 52-week highBottom 5%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 32%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 10%
- Upside to consensus price targetBottom 9%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 4%
- Maximum drawdown, 3 yearsBottom 34%
- Beta vs S&P 500 (lower is better)Bottom 16%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -27.4% | — | Bottom 44% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -5.9%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -59.94%
- Shareholder yield
- -59.94%
- Share count change, 1 year
- +21.9%
- Share count change, 3-year CAGR
- +7.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -6.8%
- Average 2-day reaction, last 8
- -2.2%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $3.60
- Target vs current price
- -2.4%
- Analysts with a rating
- 17
- Share rating Buy or Strong Buy
- 41%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | -39.7% | +2.8% | +4.1% | +6.6% | — |
| Apr 27, 2026 | +19.4% | -1.5% | -6.1% | -16.2% | -52.8% |
| Feb 24, 2026 | +0.0% | -21.2% | -28.3% | -36.7% | -45.7% |
| Oct 29, 2025 | -6.9% | -6.4% | -16.3% | +15.4% | +9.1% |
| Jul 29, 2025 | +3.4% | -2.8% | -10.9% | -17.9% | +24.2% |
| May 1, 2025 | +3.4% | +13.8% | +31.7% | +83.6% | +102.9% |
| Feb 25, 2025 | -10.7% | +0.0% | -12.4% | -13.2% | +75.9% |
| Nov 13, 2024 | +14.6% | -2.2% | -17.3% | +17.3% | -5.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | -$0.34 | -$0.24 | -39.7% | — |
| Apr 27, 2026 | -$0.25 | -$0.31 | +19.4% | — |
| Feb 24, 2026 | -$0.31 | -$0.31 | +0.0% | — |
| Oct 29, 2025 | -$0.31 | -$0.29 | -6.9% | — |
| Jul 29, 2025 | -$0.28 | -$0.29 | +3.4% | — |
| May 1, 2025 | -$0.28 | -$0.29 | +3.4% | — |
| Feb 25, 2025 | -$0.31 | -$0.28 | -10.7% | — |
| Nov 13, 2024 | -$0.35 | -$0.41 | +14.6% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -23.49% | — | — | Bottom 22% |
| Earnings yield | -32.79% | — | — | Bottom 22% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +1.2%
- 200-day average slope (20 days)
- -10.1%
- Distance from 50-day average
- -2.4%
- Distance from 200-day average
- -44.2%
- RSI (14)
- 37.5
- Relative volume
- 1.10×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 24.1%
- Volatility vs own 5-year history
- 0th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.90
- Correlation with S&P 500
- 0.31
- Current drawdown from 1-year high
- -74.7%
- Maximum drawdown, 3 years
- -79.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 20, 2021 | Apr 12, 2023 | -92.7% | 392 days | Not yet recovered |
| Feb 19, 2021 | Aug 3, 2021 | -52.5% | 114 days | 5 days (Aug 10, 2021) |
| Jan 20, 2021 | Feb 1, 2021 | -21.3% | 8 days | 10 days (Feb 16, 2021) |
| Oct 13, 2020 | Nov 2, 2020 | -18.3% | 14 days | 2 days (Nov 4, 2020) |
| Dec 15, 2020 | Jan 11, 2021 | -17.9% | 17 days | 6 days (Jan 20, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $281.5M
- EPS, diluted (TTM)
- -$1.21
- Revenue (TTM)
- $0
- 52-week range
- $2.83 – $15.74
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $19.2M | $6.3M | $2.8M | $80.0M | $0 |
| Gross profit | -$50.5M | -$70.4M | -$69.0M | $16.6M | -$1.4M |
| Operating income | -$81.1M | -$112.6M | -$110.7M | -$21.9M | -$84.8M |
| Net income | -$80.8M | -$109.9M | -$97.3M | -$9.7M | -$74.9M |
| EPS (diluted) | -$2.22 | -$2.35 | -$1.59 | -$0.16 | -$1.18 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$21.7M | -$16.6M | -$17.7M | -$17.3M | -$19.6M | -$20.3M | -$18.9M | -$26.2M |
| EPS (diluted) | -$0.35 | -$0.31 | -$0.28 | -$0.28 | -$0.31 | -$0.31 | -$0.25 | -$0.34 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$78.5M | -$97.0M | -$91.0M | -$2.2M | -$60.1M |
| Capital expenditure | -$1.7M | -$2.0M | -$508,000 | -$278,000 | -$314,000 |
| Free cash flow | -$80.2M | -$99.0M | -$91.5M | -$2.5M | -$60.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $182.9M | $80.8M | $117.3M | $2.7M | $168.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $318.8M
- Total assets
- $324.0M
- Total liabilities
- $13.3M
- Total debt
- $5.3M
- Net debt
- -$43.2M
- Shareholders’ equity
- $310.7M
As of Jun 30, 2026 (filed Jul 30, 2026).
Short interest
- Shares sold short
- 7,194,912
- Days to cover
- 5.87
- Change vs previous report
- +2.5%
FINRA short interest, settlement date Sep 15, 2026.